Q-omics provides the consensus-scored KDM6A profile across patient tissues and cancer cell-line models. KDM6A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KDM6A is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, KDM6A RNA expression shows 20,648 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where KDM6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM6A survival associations across molecular data types. KDM6A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM6A RNA expression–survival associations across cancer types. High KDM6A expression shows unfavorable associations in MESO and LUSC, but favorable associations in KIRC, SKCM, SCLC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KDM6A RNA expression.
This table summarizes KDM6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KDM6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM6A shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in CHOL, LIHC and ESCA. The THCA box plot shows higher KDM6A RNA expression in normal versus tumor tissue (log2 FC = −0.743, t-test p < 0.001).
This table shows molecular features associated with KDM6A in patient tissues and cancer cell lines. In patient samples, KDM6A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KDM6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
